Boulogne Billancourt, France, March 31, 2021 –(PR.com)– The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre announce the conclusion of a strategic Research Collaboration & Optional License Agreement concerning several targets in the field of immuno-oncology.
This strategic partnership between Y-Biologics and Pierre Fabre follows the signing of a letter of intent in November 2020 and the subsequent testing of Y-Biologic’s monoclonal antibodies on a first tumor microenvironment (TME) target selected by Pierre Fabre. This initial testing proved to be conclusive and confirmed the opportunity for Y-Biologics and Pierre Fabre to strengthen their partnership. To know more
